Dr Bisogno speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from a randomised phase III clinical trial of 6 months maintenance chemotherapy for children with the rare disease rhabdomyosarcoma.
For those receiving the low dose chemotherapy following initial treatments, 5 year overall survival improved from 73.7% to 86.5%, which is the first improvement in this indication for more than 30 years.
For more detail, watch Dr Bisogno present the data in a press conference here, or read our news coverage here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.